Benoit Demuynck, Justine Flipo, Nabil Kaci, Carl Dambkowski, Morgan Paull, Elena Muslimova, Bhavik P Shah, Laurence Legeai-Mallet
Achondroplasia, the most common form of disproportionate short stature, is caused by gain-of-function point mutations in fibroblast growth factor receptor 3 (FGFR3). Abnormally elevated activation of FGFR3 modulates chondrocyte proliferation and differentiation via multiple signaling pathways, such as the MAPK pathway. Using a mouse model mimicking achondroplasia (Fgfr3Y367C/+), we have previously shown that daily treatment with infigratinib (BGJ398), a selective and orally bioavailable FGFR1-3 inhibitor, at a dose of 2 mg/kg, significantly increased bone growth...
April 9, 2024: Journal of Bone and Mineral Research